Simvastatin: Brands, Price & Uses in Bangladesh

Simvastatin is an HMG-CoA reductase inhibitor (statin) indicated for the following uses:

Established / FDA-approved uses

• Primary hyperlipidemia and mixed dyslipidemia - to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides, and to increase HDL-cholesterol, as an adjunct to diet when response to diet and other non-drug measures alone is inadequate.
• Reduction of the risk of cardiovascular events (myocardial infarction, stroke, revascularization procedures, and cardiovascular death) in patients at high risk of coronary heart disease (established coronary heart disease, diabetes, peripheral vessel disease, or history of stroke), regardless of baseline cholesterol level.
• Homozygous familial hypercholesterolemia - to reduce total and LDL cholesterol, usually as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
• Heterozygous familial hypercholesterolemia in adolescent patients (10-17 years, at least one year post-menarche in girls) after an adequate trial of diet therapy has failed.
• Hypertriglyceridemia and primary dysbetalipoproteinemia, as an adjunct to diet.

Adjunct / combination therapy

Simvastatin is used as an adjunct to diet in all indications above; in familial hypercholesterolemia it may be combined with other lipid-lowering therapies such as LDL apheresis under specialist supervision.

This medicine does not treat existing atherosclerotic plaque directly but reduces the risk of future cardiovascular events through cholesterol lowering; it works best combined with dietary changes, exercise, weight control, and smoking cessation.

General Dosing Principles

Simvastatin is taken orally, once daily in the evening, with or without food, as evening dosing coincides with the body's peak endogenous cholesterol synthesis. The dose should be individualized according to baseline LDL-cholesterol, the goal of therapy, and patient response, with dose adjustments made at intervals of no less than 4 weeks.

Dose Restrictions with Interacting Drugs

See Drug Interactions for mandatory maximum dose limits when Simvastatin is combined with verapamil, diltiazem, amiodarone, amlodipine, or ranolazine.

Renal Impairment

In patients with severe renal impairment (creatinine clearance below 30 mL/min), Simvastatin should be started at 5 mg once daily with close monitoring, as systemic exposure may be increased.

Hepatic Impairment

Simvastatin is contraindicated in active liver disease (see Contraindications). Liver function should be assessed before starting therapy.

The 80 mg Dose

The 80 mg dose of Simvastatin should be used only in patients who have already been taking it for 12 months or more without evidence of muscle toxicity, because of an increased risk of myopathy and rhabdomyolysis at this dose; it should not generally be used to start therapy.

Most patients tolerate Simvastatin well. Reported side effects include:

Common

• Headache
• Gastrointestinal disturbances - abdominal pain, constipation, flatulence, nausea, diarrhea
• Upper respiratory tract infection symptoms
• Mild, transient muscle aches

Less Common / Serious

• Myopathy and rhabdomyolysis - unexplained muscle pain, tenderness, or weakness, especially with fever or malaise, may signal muscle breakdown; report promptly (see Precautions and Warnings).
• Elevated liver transaminases - usually asymptomatic and reversible on discontinuation; rare reports of hepatitis and liver failure.
• New-onset or worsening hyperglycemia/diabetes.
• Peripheral neuropathy (rare).
• Hypersensitivity reactions including rash, pruritus, and rarely angioedema.
• Memory impairment or confusion (rare, generally reversible on stopping the drug).